Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7159481 | 0.74 | ALOX15 (0.34) | — | |
| SCHEMBL3170254 | 0.74 | RXRA (0.44) | — | |
| SCHEMBL21238596 | 0.74 | BCHE (0.37) | BCHECES1POLBL3MBTL1 | |
| SCHEMBL7843935 | 0.74 | BCHE (0.37) | BCHECES1 | |
| SCHEMBL4709608 | 0.73 | BCHE (0.36) | BCHECES1 | |
| SCHEMBL4709614 | 0.73 | BCHE (0.36) | BCHECES1 | |
| SCHEMBL4709163 | 0.73 | BCHE (0.36) | BCHECES1 | |
| SCHEMBL14159910 | 0.73 | BCHE (0.36) | BCHECES1 | |
| SCHEMBL482796 | 0.73 | TSHR (0.42) | BCHECES1POLBL3MBTL1 | |
| SCHEMBL545862 | 0.71 | BCHE (0.47) | BCHECES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391093-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-9573906-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573906-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573906-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2910549-A1 | 1,2,3,4-TETRAHYDRO-1,1,4,4-TETRAMETHYLNAPHTHALENE DERIVATIVES USEFUL AS RXR MODULATORS FOR TREATING ALZHEIMER'S DISEASE AND CANCER | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2910549-A1 | 1,2,3,4-TETRAHYDRO-1,1,4,4-TETRAMETHYLNAPHTHALENE DERIVATIVES USEFUL AS RXR MODULATORS FOR TREATING ALZHEIMER'S DISEASE AND CANCER | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, A body corporate of the State of Arizona, acting for and on | 2014-11-20 | — | — | US | disclosed |
| EP-1935869-A1 | Retinoids for the treatment of emphysema | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| EP-1935869-A1 | Retinoids for the treatment of emphysema | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| CN-1321101-C | New retinoids for the treatment of emphysema | HOFFMANN LA ROCHE CO LTD (CH) | 2007-06-13 | — | — | CN | disclosed |
| WO-2007022437-A2 | THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND METABOLIC DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | INCYTE CORPORATION | 2005-02-17 | — | — | US | disclosed |
| US-6777418-B2 | FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-08-17 | — | — | US | disclosed |
| CN-1468207-A | Novel retinoid compounds for the treatment of emphysema | - | 2004-01-14 | — | — | CN | disclosed |
| EP-1324970-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002028810-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391093-B2 | Therapeutic compounds | PSEN1, PSEN2, MAPT | BCHE 19/4885CES1 2286/4885POLB 3099/4885 |
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | RXRA, RXRG, RXRB | BCHE 1219/4885CES1 461/4885POLB 1593/4885 |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | PSEN1, PSEN2, MAPT | BCHE 19/4885CES1 2286/4885POLB 3099/4885 |
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | HSD17B10, IDH2, INSR | BCHE 3556/4885CES1 238/4885POLB 4523/4885 |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | MAPT, PSEN1, PSEN2 | BCHE 17/4885CES1 2562/4885POLB 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.